Cabozantinib
As of the edition of 20 October 2026, Cabozantinib is a small molecule: marketed, first approved in 2012 (US); acts on KDR; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Cometriq
- First approved
- 29 November 2012 (US)
- Approvals on record
- 14 in 4 regions
- Holder of the most recent approval
- Takeda; 3 holders in all
- Registered trials
- 249, 33 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones; Lungs and airways
US protection
US protection ends in 2032.
The last listed US exclusivity ends in 2032. The application that gives this date is held by Exelixis.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product24 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 24 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Cabozantinib.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 8 | 0 | 0 |
| Phase 1 | 46 | 26 | 17 | 3 |
| Phase 2 | 165 | 57 | 66 | 28 |
| Phase 3 | 23 | 6 | 14 | 2 |
| Phase 4 | 5 | 1 | 4 | 0 |
| All trials | 249 |